Literature DB >> 6301976

Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.

H Okada, H Tanaka, N Okada.   

Abstract

Guinea-pig line 10 tumor (GPL10) cells, which were transplantable in strain 2 guinea-pigs, gained the capacity to activate the homologous alternative complement pathway (ACP) following infection with ultraviolet-irradiated Sendai virus (UV-SV). The ACP activation of homologous serum on the UV-SV-infected GPL10 cells (UV-SV-GPL10 cells) resulted in cytolysis of the tumor cells. This indicates that UV-SV infection induced not only the capacity to activate complement on the GPL10 cells, but also made them sensitive to complement attack, because GPL10 cells have been demonstrated to be resistant to the reaction of homologous complement via the classical pathway in the presence of rabbit antibody. Furthermore, UV-SV-GPL10 cells prepared with as little as 0.1 plaque-forming unit equivalent of UV-SV per cell showed suppressed growth in syngeneic strain 2 guinea-pigs. The essential role of complement in the elimination of UV-SV-GPL10 cells in vivo was confirmed by demonstrating that UV-SV-GPL10 could grow in guinea-pigs whose complement had been depleted by administration of cobra venom factor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301976      PMCID: PMC1454102     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Activation of the alternative pathway of guinea pig complement by Sendai virus-treated cells.

Authors:  N Okada; H Shibuta; H Okada
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

2.  Lysis of RSV-transformed Japanese quail cells by a factor from normal quail serum.

Authors:  Y Yoshikawa; K Yamanouchi; M Hishiyama; K Kobune
Journal:  Int J Cancer       Date:  1978-05-15       Impact factor: 7.396

3.  Activation of complement by spontaneous leukemic cells of AKR mice.

Authors:  N Okada; H Okada
Journal:  Int J Cancer       Date:  1978-09-15       Impact factor: 7.396

4.  Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.

Authors:  I McConnell; G Klein; T F Lint; P J Lachmann
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

5.  Lysis of tumor cells by antibody and complement. 1. Lack of correlation between antigen content and lytic susceptibility.

Authors:  S H Ohanian; T Borsos; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1973-05       Impact factor: 13.506

6.  Mechanism of cytolysis by complement.

Authors:  M M Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

7.  Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane.

Authors:  H Okada; T Baba
Journal:  Nature       Date:  1974-04-05       Impact factor: 49.962

8.  Homologous species restriction in lysis of erythrocytes by terminal complement proteins.

Authors:  G M Hänsch; C H Hammer; P Vanguri; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

10.  Complement-dependent B-cell activation by cobra venom factor and other mitogens?

Authors:  P Dukor; G Schumann; R H Gisler; M Dierich; W König; U Hadding; D Bitter-Suermann
Journal:  J Exp Med       Date:  1974-02-01       Impact factor: 14.307

View more
  2 in total

1.  Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.

Authors:  H Okada; N Wakamiya; N Okada; S Kato
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement.

Authors:  N Wakamiya; N Okada; Y L Wang; T Ito; S Ueda; S Kato; H Okada
Journal:  Jpn J Cancer Res       Date:  1989-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.